FDA Warns of Unapproved Hair-Loss Product Linked to Side Effects
By I. Edwards HealthDay Reporter
THURSDAY, April 24, 2025 — A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left them battling sexual side effects, depression and even thoughts of suicide.
Now, the U.S. Food and Drug Administration (FDA) is warning the public about the risks.
The FDA warning is about a topical spray version of finasteride, a drug often sold online by telehealth companies like Hims, Keeps and Ro, The Wall Street Journal reported.
While the pill form of finasteride, known by the brand name Propecia, is FDA-approved to treat hair loss, the spray version is not.
"FDA has become aware of reports of adverse events involving compounded topical finasteride products potentially putting consumers at risk," the April 22 statement said.
"Currently, there is no FDA-approved topical formulation of finasteride," it continued. "Compounded topical finasteride products do not have FDA-approved labeling. There are potential serious risks associated with the use of compounded topical finasteride products."
The FDA warning follows a recent Wall Street Journal report describing men who said they experienced side effects after using finasteride prescriptions purchased from the telehealth companies Hims and Keeps.
Reported side effects include "erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido and testicular pain," the FDA said.
The FDA also warned that the spray could pose a risk to others, especially women. Finasteride can cause birth defects in male babies, so women are advised not to come in contact with the drug, the warning added.
Some users told the FDA that their doctors had said the spray version would not cause side effects.
Online health companies are allowed to sell these sprays through compounding pharmacies, which create drugs when patients need an alternative to FDA-approved medications.
While it's all legal, these companies are not held to the same advertising standards as traditional drugmakers, The Wall Street Journal reports.
In previous statements, both Hims and Keeps said they inform customers about potential risks on their websites and packaging.
Sources
- The Wall Street Journal, April 23, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Nearly Half of Americans Breathe Unhealthy Air, New Report Finds
FRIDAY, April 25, 2025 — Breathing the air in nearly half of the United States could be putting the health of residents at risk. A new American Lung Association report...
Four-Gene Combo Might Predict Lethality Of Stomach Cancer
FRIDAY, April 25, 2025 — Four specific genes serve as a telltale clue to how potentially deadly stomach cancers will develop and progress, a new study says. Testing for...
Colon Cancer Screening Program Cut Cases, Deaths, Eliminated Racial Gaps
FRIDAY, April 25, 2025 -- A Kaiser Permanente colon cancer screening initiative put a huge dent in cancer cases and deaths over two decades, a new study says. The systematic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.